Compare EQT & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EQT | ZTS |
|---|---|---|
| Founded | 1925 | 1952 |
| Country | United States | United States |
| Employees | 1873 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.9B | 32.5B |
| IPO Year | 1994 | 2012 |
| Metric | EQT | ZTS |
|---|---|---|
| Price | $53.18 | $77.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 12 |
| Target Price | $69.15 | ★ $154.18 |
| AVG Volume (30 Days) | ★ 6.3M | 4.4M |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | 1.12% | ★ 1.86% |
| EPS Growth | ★ 635.56 | 10.05 |
| EPS | ★ 2.70 | 1.42 |
| Revenue | $8,644,211,000.00 | ★ $9,467,000,000.00 |
| Revenue This Year | $20.28 | $5.63 |
| Revenue Next Year | N/A | $4.77 |
| P/E Ratio | ★ $19.46 | $53.55 |
| Revenue Growth | ★ 63.92 | 2.28 |
| 52 Week Low | $47.94 | $71.47 |
| 52 Week High | $68.24 | $160.48 |
| Indicator | EQT | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 55.11 | 49.15 |
| Support Level | $50.58 | $73.42 |
| Resistance Level | $54.87 | $78.02 |
| Average True Range (ATR) | 1.34 | 1.95 |
| MACD | 0.37 | 0.46 |
| Stochastic Oscillator | 68.74 | 51.40 |
EQT is an independent natural gas production company. It focuses its operations in the cores of the Marcellus and Utica shales, located in the Appalachian Basin in the Eastern United States. Its main customers include marketers, utilities, and industrial operators in the Appalachian Basin. The company has three reportable segments in production, gathering, and its transmission segment, which is now an operated joint venture with Blackstone. All the firm's operating revenue is generated in the US, with most revenue flowing from the Marcellus Shale field and through the sale of natural gas.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.